- Home
- BCG vs SYRS Comparison
BCG vs SYRS Comparison
Compare BCG & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- SYRS
- Stock Information
- Founded
- BCG 2016
- SYRS 2011
- Country
- BCG United States
- SYRS United States
- Employees
- BCG N/A
- SYRS N/A
- Industry
- BCG
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- SYRS Health Care
- Exchange
- BCG Nasdaq
- SYRS Nasdaq
- Market Cap
- BCG 54.3M
- SYRS 44.0M
- IPO Year
- BCG N/A
- SYRS 2016
- Fundamental
- Price
- BCG $2.80
- SYRS $1.96
- Analyst Decision
- BCG
- SYRS Strong Buy
- Analyst Count
- BCG 0
- SYRS 3
- Target Price
- BCG N/A
- SYRS $5.00
- AVG Volume (30 Days)
- BCG 12.9K
- SYRS 353.6K
- Earning Date
- BCG 08-15-2024
- SYRS 11-12-2024
- Dividend Yield
- BCG N/A
- SYRS N/A
- EPS Growth
- BCG N/A
- SYRS N/A
- EPS
- BCG N/A
- SYRS N/A
- Revenue
- BCG $161,897,000.00
- SYRS $4,149,000.00
- Revenue This Year
- BCG N/A
- SYRS N/A
- Revenue Next Year
- BCG N/A
- SYRS $614.29
- P/E Ratio
- BCG N/A
- SYRS N/A
- Revenue Growth
- BCG N/A
- SYRS N/A
- 52 Week Low
- BCG $2.60
- SYRS $1.43
- 52 Week High
- BCG $16.61
- SYRS $8.17
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- SYRS 44.14
- Support Level
- BCG N/A
- SYRS $1.85
- Resistance Level
- BCG N/A
- SYRS $2.03
- Average True Range (ATR)
- BCG 0.00
- SYRS 0.14
- MACD
- BCG 0.00
- SYRS 0.08
- Stochastic Oscillator
- BCG 0.00
- SYRS 27.66
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.